Paper16732016
Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease.
Targher G and 8 others. Diabetes Care, 2006. Cited by 319 papers, by iCite.
Cite this record
ConductScience Library. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Papers, record 16732016. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/16732016
- Disease
- type 1 diabetes mellitus304 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease.
- PubMed
Connected records2
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carotid Arteries | Major topic |
| Carotid Artery Diseases | Major topic |
| Fatty Liver | Major topic |
| Liver | Major topic |
| Adult | |
| Blood Glucose | |
| Body Mass Index | |
| Body Weight | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Triglycerides |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT06348706 | Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes | Results |
Source ClinicalTrials.gov
Cited by147
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 319 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41767367 | A pilot study on a combined non-invasive screening test for metabolic dysfunction-associated steatotic liver disease and type 2 diabetes. | Front Endocrinol (Lausanne) | 2026 | https://conductscience.org/library/papers/41767367 | PubMed |
| 40123646 | Non-alcoholic fatty liver disease (NAFLD) and its association to cardiovascular disease: A comprehensive meta-analysis. | JRSM Cardiovasc Dis | 2025 | https://conductscience.org/library/papers/40123646 | PubMed |
| 39868507 | Association Between Liver Fibrosis and Risk of Incident Stroke and Mortality: A Large Prospective Cohort Study. | J Am Heart Assoc | 2025 | https://conductscience.org/library/papers/39868507 | PubMed |
| 39231620 | Cardiovascular Death and Liver Disease: Mortality Trends and Disparities. | Clin Med Res | 2024 | https://conductscience.org/library/papers/39231620 | PubMed |
| 39086662 | Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/39086662 | PubMed |
| 39011212 | Association of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) With an Increased Risk of Congestive Heart Failure in Hospitalized Patients With Cirrhosis: A Propensity Score-Matched Analysis. | Cureus | 2024 | https://conductscience.org/library/papers/39011212 | PubMed |
| 38213666 | Clinical Management of Non-alcoholic Steatohepatitis and the Role of the Cardiologist. | Eur Cardiol | 2023 | https://conductscience.org/library/papers/38213666 | PubMed |
| 38068433 | How Cardiac Fibrosis Assessed via T1 Mapping Is Associated with Liver Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. | J Clin Med | 2023 | https://conductscience.org/library/papers/38068433 | PubMed |
| 37764755 | New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk. | Nutrients | 2023 | https://conductscience.org/library/papers/37764755 | PubMed |
| 37701352 | Association of nonalcoholic fatty liver disease and carotid media-intima thickness: A systematic review and a meta-analysis. | Health Sci Rep | 2023 | https://conductscience.org/library/papers/37701352 | PubMed |
| 37675086 | Opportunistic screening at chest computed tomography: literature review of cardiovascular significance of incidental findings. | Cardiovasc Diagn Ther | 2023 | https://conductscience.org/library/papers/37675086 | PubMed |
| 37663203 | Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease. | Diabetes Metab Syndr Obes | 2023 | https://conductscience.org/library/papers/37663203 | PubMed |
| 37417238 | Management of Stroke in Patients With Chronic Liver Disease: A Practical Review. | Stroke | 2023 | https://conductscience.org/library/papers/37417238 | PubMed |
| 36008083 | Shared Mechanisms between Cardiovascular Disease and NAFLD. | Semin Liver Dis | 2022 | https://conductscience.org/library/papers/36008083 | PubMed |
| 35990786 | Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH). | Can Liver J | 2022 | https://conductscience.org/library/papers/35990786 | PubMed |
| 35557545 | Non-alcoholic Fatty Liver Disease Is Associated With Cardiovascular Outcomes in Subjects With Prediabetes and Diabetes: A Prospective Community-Based Cohort Study. | Front Cardiovasc Med | 2022 | https://conductscience.org/library/papers/35557545 | PubMed |
| 35467297 | General Overview About the Current Management of Nonalcoholic Fatty Liver Disease. | Clin Drug Investig | 2022 | https://conductscience.org/library/papers/35467297 | PubMed |
| 35264962 | Astragaloside IV Relieves Atherosclerosis and Hepatic Steatosis via MAPK/NF-κB Signaling Pathway in LDLR-/- Mice. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35264962 | PubMed |
| 35232007 | Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals. | Clin Mol Hepatol | 2022 | https://conductscience.org/library/papers/35232007 | PubMed |
| 34933963 | Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis. | Open Heart | 2021 | https://conductscience.org/library/papers/34933963 | PubMed |
Drugs1
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets |
|---|---|---|---|---|
| VILDAGLIPTIN | CHEMBL142703 | Results | 1 | https://conductscience.org/library/drugs/CHEMBL142703 |
Source ChEMBL
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Comments and corrections
- References
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/16732016
GET https://conductscience.org/api/papers/v1/16732016/cited_by?page=2